April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…
April 22, 2024 Columns by Desiree Lama Learning to manage cognitive impairment with multiple sclerosis Upon commencing my undergraduate studies at the University of Texas (UT) at Austin, I pursued a major in prehealth neuroscience. I had decided to pursue this degree shortly after my diagnosis of relapsing-remitting multiple sclerosis in 2016, during my senior year of high school. My hope in choosing the…
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Earlier Ocrevus lowers MS progression risk over 10 years Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on the therapy in the controlled part of the trials, compared with…
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). That’s according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…